Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
41 Results for "
Pkmyt1
" in MedChemExpress (MCE) Product Catalog:
Products (41)
41 Results for "Pkmyt1" in MCE Product Catalog:
11
11 Cited Publications
Synonyms: RP-6306
lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects [1].
2
2 Cited Publications
GSK-1520489A is a PKMYT1 (active protein kinase) inhibitor (IC50=115 nM, Ki=10.94 nM) [1].
Art. -Nr.: HY-169946
CAS. Nr.: 3047737-15-2
WEE1/PKMYT1-IN-1 (compound 75) is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
Art. -Nr.: HY-170517
CAS. Nr.: 3065631-84-4
Target:
Forschungsgebiete:
PKMYT1-IN-8 (Compound 137) is the inhibitor for PKMYT1 with an IC50 of 9 nM. PKMYT1-IN-8 inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2with IC50s of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. PKMYT1-IN-8 inhibits the proliferation of cancer cell OVCAR3 with GI50 of 2.02 μM [1].
Synonyms: (Rac)-RP-6306
(Rac)-lunresertib (compound 181) is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. (Rac)-lunresertib (compound 181) has anticancer effects [1].
Synonyms: (R)-RP-6306
(R)-lunresertib ((R)-RP-6306) (compound 183) is a membrane-associated tyrosine- and threonine-specific cdc2 inhibitory kinase (Myt1/PKMYT1) inhibitor with an IC50 of 1360 nM. (R)-lunresertib is applicable to Myt1-mediated cancer-related research [1].
Art. -Nr.: HY-163491
CAS. Nr.: 3033609-84-3
PKMYT1-IN-2 (compound 2) is a potent PKMYT1 inhibitor with an IC50 of 5.7 nM. PKMYT1-IN-2 inhibits the growth of HCC1569 cells with an IC50 of 22 nM [1].
Art. -Nr.: HY-RS10605
Target:
Forschungsgebiete:
PKMYT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKMYT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS16738
Target:
Forschungsgebiete:
Pkmyt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pkmyt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS23175
Target:
Forschungsgebiete:
Pkmyt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pkmyt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-175819
CAS. Nr.: 717094-37-6
PD-166285 is a PKMYT1 inhibitor, with an IC50 value of 17 nM. PD166285 shows strong antiproliferative effects against CCNE1-amplified OVCAR3 cells (IC50 = 0.14 μM) and HCC1569 cells (IC50 = 0.21 μM). PD166285 induces apoptosis and arrests CCNE1-amplified HCC1569 cells at the G1/S phase of the cell cycle. PD166285 can be used for the research of PKMYT1-targeted therapies for CCNE1-amplified cancers [1].
Art. -Nr.: HY-172759
CAS. Nr.: 3055031-36-9
PKMYT1-IN-9 is a highly selective and orally active PKMYT1 inhibitor (IC50: 4.4 nM). PKMYT1-IN-9 shows more selective for PKMYT1 than WEE1 (IC50: 32.4 μM). PKMYT1-IN-9 exhibits antitumor activity [1].
Art. -Nr.: HY-175817
PKMYT1-IN-10 is a selective PKMYT1 inhibitor with an IC50 of 3 nM. PKMYT1-IN-10 inhibits colony formation, induces apoptosis, and induces S-phase cancer cell cycle arrest. PKMYT1-IN-10 exhibits liver microsomal stability, favorable plasma stability, minimal CYPs inhibition. PKMYT1-IN-10 can be used for the studies of ovarian cancer and breast cancer [1].
Art. -Nr.: HY-169946A
CAS. Nr.: 3047759-59-8
WEE1/PKMYT1-IN-2 is the axial chiral P configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
Art. -Nr.: HY-169946B
CAS. Nr.: 3047759-60-1
WEE1/PKMYT1-IN-3 is the axial chiral M configuration of WEE1/PKMYT1-IN-1 (HY-169946). WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity [1].
Art. -Nr.: HY-163490
CAS. Nr.: 3033609-83-2
PKMYT1-IN-1 (Compound 1) is an inhibitor for membrane-associated tyrosine and threonine kinase (PKMYT1), with an IC50 of 8.8 nM. PKMYT1-IN-1 inhibits proliferation of tumor cell HCC1569 with IC50 of 42 nM [1].
Myt1-IN-1 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132) [1].
Myt1-IN-3 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50s of <10 nM (WO2021195782 A1, compound 95) [1].
Art. -Nr.: HY-159937
CAS. Nr.: 2986404-30-0
PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and < [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
